Certara Signs Partnership Agreement with ChemAxon

Certara’s D360 to offer access to ChemAxon’s MarvinSketch and JChem Cartridge for Oracle.

ST. LOUIS--(BUSINESS WIRE)--Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through clinical development, announced that Certara and ChemAxon have signed a partnership agreement. The partnership will focus on providing seamless access to ChemAxon’s MarvinSketch and JChem Cartridge for Oracle via Certara’s D360.

“We are very happy to have Certara join the expanding list of major application providers integrating our platform within their solutions. This gives customers tremendous flexibility to have what best suits their needs being provided by an established partner group”

D360 is an integrated solution for query, analysis and visualization of scientific data. It is used by pharmaceutical and biotech companies to provide unified access to disparate data sources throughout drug discovery and development, greatly improving research productivity. The agreement with ChemAxon provides standard D360 support for ChemAxon’s popular chemical structure sketching tool, MarvinSketch, and JChem Chemistry data cartridge, which are used by many drug discovery scientists across the industry.

“We are very pleased to partner with ChemAxon to provide Marvin and JChem integrations as a standard D360 product capability,” said Jonathan Feldmann, Vice President of Scientific Informatics at Certara, in making the announcement. “Part of the value of D360 is being able to easily connect to an organization’s existing infrastructure, and we are increasingly finding that ChemAxon is part of the core chemistry infrastructure. We are now able to seamlessly integrate and deliver other data types, such as biologic assay or preclinical safety data with chemistry data from ChemAxon via simple queries that any user can develop.”

“We are very happy to have Certara join the expanding list of major application providers integrating our platform within their solutions. This gives customers tremendous flexibility to have what best suits their needs being provided by an established partner group,” said Alex Drijver, CEO of ChemAxon. “It also underlines our commitment to both partners and customers in maintaining a flexible business model in which the customer chooses whether to use the ChemAxon front end tools or other solutions like D360.”

About Certara

Certara is dedicated to improving human health through a broad spectrum of software products and consulting services, from molecular discovery through clinical development, with special focus on supporting translational approaches to drug development. Certara was formed by uniting industry leaders Tripos, provider of innovative scientific software solutions and services enabling life science researchers to improve the efficiency of molecular discovery; Simcyp, a research-based company providing predictive pharmacokinetic and pharmacodynamics tools, workshops, and consultancy services; and Pharsight Corporation, provider of software and scientific consulting services to improve productivity and decision-making in preclinical and clinical drug development. Each Certara family brand has a primary focus on a key phase within the drug discovery and development process; combined, they offer a unique set of capabilities for modeling, analysis, and simulation with scientific informatics that can enable the cross-disciplinary approaches necessary for translational science initiatives.

About ChemAxon

ChemAxon is a leader in providing cheminformatics software platforms and desktop applications for the biotechnology, pharmaceutical and agrochemical industries. With core capabilities for structure visualization, search and management, property prediction, virtual synthesis, screening and drug design, ChemAxon focuses upon active interaction with users and software portability to create powerful, cost effective cross platform solutions that power modern cheminformatics and chemical communication. The company is privately owned with European headquarters in Budapest, US East Coast headquarters in Cambridge, MA, and sales and support offices in Europe, Japan and across North America.